|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Altekruse SF, McGlynn KA, Dickie LA and
Kleiner DE: Hepatocellular carcinoma confirmation, treatment, and
survival in surveillance, epidemiology, and end results registries,
1992–2008. Hepatology. 55:476–482. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bosch FX, Ribes J, Cléries R and Diaz M:
Epidemiology of hepatocellular carcinoma. Clin Liver Dis.
9:191–211. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tanaka S and Arii S: Molecularly targeted
therapy for hepatocellular carcinoma. Cancer Sci. 100:1–8. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lau WY and Lai EC: The current role of
radiofrequency ablation in the management of hepatocellular
carcinoma: A systematic review. Ann Surg. 249:20–25. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thorgeirsson SS and Grisham JW: Molecular
pathogenesis of human hepatocellular carcinoma. Nat Genet.
31:339–346. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yamashita T, Forgues M, Wang W, Kim JW, Ye
Q, Jia H, Budhu A, Zanetti KA, Chen Y, Qin LX, et al: EpCAM and
alpha-fetoprotein expression defines novel prognostic subtypes of
hepatocellular carcinoma. Cancer Res. 68:1451–1461. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
Biffoni M, Todaro M, Peschle C and De Maria R: Identification and
expansion of human colon-cancer-initiating cells. Nature.
445:111–115. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100:pp.
3983–3988. 2003; View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bonnet D and Dick JE: Human acute myeloid
leukemia is organized as a hierarchy that originates from a
primitive hematopoietic cell. Nat Med. 3:730–737. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim H, Choi GH, Na DC, Ahn EY, Kim GI, Lee
JE, Cho JY, Yoo JE, Choi JS and Park YN: Human hepatocellular
carcinomas with ‘Stemness’-related marker expression: Keratin 19
expression and a poor prognosis. Hepatology. 54:1707–1717. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Terris B, Cavard C and Perret C: EpCAM, a
new marker for cancer stem cells in hepatocellular carcinoma. J
Hepatol. 52:280–281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang SL, Liu LP, Yang S, Liu L, Ren JW,
Fang X, Chen GG and Lai PB: Preoperative serum α-fetoprotein and
prognosis after hepatectomy for hepatocellular carcinoma. Br J
Surg. 103:716–724. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Reya T and Clevers H: Wnt signalling in
stem cells and cancer. Nature. 434:843–850. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ma S, Tang KH, Chan YP, Lee TK, Kwan PS,
Castilho A, Ng I, Man K, Wong N, To KF, et al: miR-130b promotes
CD133(+) liver tumor-initiating cell growth and self-renewal via
tumor protein 53-induced nuclear protein 1. Cell Stem Cell.
7:694–707. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Altman DG, McShane LM, Sauerbrei W and
Taube SE: Reporting recommendations for tumor marker prognostic
studies (REMARK): Explanation and elaboration. PLoS Med.
9:e10012162012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Moons KG, Altman DG, Reitsma JB and
Collins GS: Transparent Reporting of a Multivariate PredictionModel
for Individual Prognosis or Development Initiative: New guideline
for the reporting of studies developing, validating, or updating a
multivariable clinical prediction model: The TRIPOD statement. Adv
Anat Pathol. 22:303–305. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chan SL, Mo F, Johnson PJ, Siu DY, Chan
MH, Lau WY, Lai PB, Lam CW, Yeo W and Yu SC: Performance of serum
α-fetoprotein levels in the diagnosis of hepatocellular carcinoma
in patients with a hepatic mass. HPB (Oxford). 16:366–372. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kang YK, Hong SW, Lee H and Kim WH:
Prognostic implications of ezrin expression in human hepatocellular
carcinoma. Mol Carcinog. 49:798–804. 2010.PubMed/NCBI
|
|
20
|
Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z,
Roskams T, Durnez A, Demetris AJ and Thorgeirsson SS:
Classification and prediction of survival in hepatocellular
carcinoma by gene expression profiling. Hepatology. 40:667–676.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yamashita T, Ji J, Budhu A, Forgues M,
Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, et al:
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating
cells with stem/progenitor cell features. Gastroenterology.
136:1012–1024. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schmelzer E, Wauthier E and Reid LM: The
phenotypes of pluripotent human hepatic progenitors. Stem Cells.
24:1852–1858. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Roskams T: Liver stem cells and their
implication in hepatocellular and cholangiocarcinoma. Oncogene.
25:3818–3822. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ishii T, Yasuchika K, Suemori H, Nakatsuji
N, Ikai I and Uemoto S: Alpha-fetoprotein producing cells act as
cancer progenitor cells in human cholangiocarcinoma. Cancer Lett.
294:25–34. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO,
Zheng BJ and Guan XY: Identification and characterization of
tumorigenic liver cancer stem/progenitor cells. Gastroenterology.
132:2542–2556. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lindgren D, Boström AK, Nilsson K, Hansson
J, Sjölund J, Möller C, Jirström K, Nilsson E, Landberg G, Axelson
H and Johansson ME: Isolation and characterization of
Progenitor-like cells from human renal proximal tubules. Am J
Pathol. 178:828–837. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Schmelzer E, Zhang L, Bruce A, Wauthier E,
Ludlow J, Yao HL, Moss N, Melhem A, McClelland R, Turner W, et al:
Human hepatic stem cells from fetal and postnatal donors. J Exp
Med. 204:1973–1987. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Richardson GD, Robson CN, Lang SH, Neal
DE, Maitland NJ and Collins AT: CD133, a novel marker for human
prostatic epithelial stem cells. J Cell Sci. 117:3539–3545. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Uchida N, Buck DW, He DP, Reitsma MJ,
Masek M, Phan TV, Tsukamoto AS, Gage FH and Weissman IL: Direct
isolation of human central nervous system stem cells. Proc Natl
Acad Sci USA. 97:pp. 14720–14725. 2000; View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yin AH, Miraglia S, Zanjani ED,
Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J and Buck
DW: AC133, a novel marker for human hematopoietic stem and
progenitor cells. Blood. 90:5002–5012. 1997.PubMed/NCBI
|
|
31
|
Yin S, Li J, Hu C, Chen X, Yao M, Yan M,
Jiang G, Ge C, Xie H, Wan D, et al: CD133 positive hepatocellular
carcinoma cells possess high capacity for tumorigenicity. Int J
Cancer. 120:1444–1450. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Parpart S, Roessler S, Dong F, Rao V,
Takai A, Ji J, Qin LX, Ye QH, Jia HL, Tang ZY and Wang XW:
Modulation of miR-29 expression by α-fetoprotein is linked to the
hepatocellular carcinoma epigenome. Hepatology. 60:872–883. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sasaki A, Kamiyama T, Yokoo H, Nakanishi
K, Kubota K, Haga H, Matsushita M, Ozaki M, Matsuno Y and Todo S:
Cytoplasmic expression of CD133 is an important risk factor for
overall survival in hepatocellular carcinoma. Oncol Rep.
24:537–546. 2010. View Article : Google Scholar : PubMed/NCBI
|
